June 3, 2015 | Israeli pharmaceutical company Teva Pharmaceutical Industries announced the launch of a generic ADHD treatment, the equivalent of the INTUNIV drug. The generic version of INTUNIV will be launched in the United States in 1, 2, 3 and 4 milligram doses. The INTUNIV drug is made up of a chemical called Guanfacine that is a non-stimulant treatment for ADHD.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments